Interview with Dejan Jovanovic, General manager, Astellas Russia
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
Address: 109147, Moscow,Russia
Tel: +7 (495) 737 0755
Web: http://www.astellas.com/worldwide.html
Pharma (the Netherlands), its Representative office was opened in Moscow in 1994. Yamanouchi Company was found on the basis of Brocades Company. In 2005 a new multinational company Astellas was found as a result of two Japanese companies’ merger – Fujisawa and Yamanouchi. Main Astellas goal is to improve people’s lives and give them hope for the future with innovative pharmaceutical products and also become a Global Category Leader in chosen therapy areas.
Astellas is among top 20 companies of the world successfully managing its business in different countries such as Japan, North America (the USA and Canada), Europe and Asia. Headcount of Astellas worldwide is more than 17 thousand people.
Russian affiliate is related to European branch – Astellas Pharma Europe. Astellas Russia is responsible for business in Russia, the Ukraine, Belarus, Kazakhstan, Azerbaijan, Armenia, Moldova, Georgia, Kirgizia, Turkmenistan, Tajikistan, Uzbekistan and Mongolia.
Astellas has 4 global corporate principals which are called STAR: Success driven, Team oriented, Adoptable and Respectful.
Russian affiliate headcount is continuingly growing. They are young and vigorous professionals who can achieve their ambitious goals. Astellas aim is to become an Employer of Choice. That is why it is trying to improve HR policy, social package and team spirit.
Infectives, Transplantation, Oncology, Pail Management and others. Astellas brand products are: Omnic, Prograf, Flemoxin Solutab, Wilprafen Solutab, Unidox Solutab, Pimafucin, Zineryt, DeNol, Phosphalugel and others.
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here
